The impact of a best practice advisory on inpatient prescribing of piperacillin-tazobactam
Main Authors: | Katherine L. Peterson, Bradley J. Tompkins, John W. Ahern, Lindsay M. Smith |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2022-01-01
|
Series: | Antimicrobial Stewardship & Healthcare Epidemiology |
Online Access: | https://www.cambridge.org/core/product/identifier/S2732494X22000122/type/journal_article |
Similar Items
-
Piperacillin/tazobactam in modern clinical practice
by: Igor Bereznyakov
Published: (2022-05-01) -
Mechanisms of Piperacillin/Tazobactam Nephrotoxicity: Piperacillin/Tazobactam-Induced Direct Tubular Damage in Mice
by: Jihyun Yang, et al.
Published: (2023-06-01) -
Impact of extended-infusion piperacillin-tazobactam in a Canadian community hospital
by: April J. Chan, et al.
Published: (2023-03-01) -
Evaluating the appropriateness of carbapenem and piperacillin-tazobactam prescribing in a tertiary care hospital in Saudi Arabia
by: Nada A Alsaleh, et al.
Published: (2020-11-01) -
Piperacillin–tazobactam as alternative to carbapenems for ICU patients
by: Benoit Pilmis, et al.
Published: (2017-11-01)